• Organic Cation Transporter Response to Olsalazine in Aedes a

  2026-04-20

  This study investigates how the mosquito Aedes aegypti eliminates foreign compounds by analyzing the excretion and gene expression responses to synthetic dyes, including the mesalamine dimer Olsalazine Sodium. The findings highlight the role of xenobiotic transporters and molecular structure in detoxification, providing a foundation for novel mosquito control strategies.

• Docetaxel in Cancer Chemotherapy: Mechanisms, Resistance & N

  2026-04-19

  Explore the multifaceted role of Docetaxel in cancer chemotherapy research, focusing on its mechanism, resistance pathways, and the impact of SMYD2-driven epigenetic regulation. Gain actionable insights for oncology assay design and discover how APExBIO's Docetaxel advances research beyond current literature.

• Pharmacokinetics and Safety of Gepotidacin in Healthy Adults

  2026-04-18

  This phase I clinical investigation characterizes the pharmacokinetics, safety, and tolerability of gepotidacin (GSK2140944), a novel triazaacenaphthylene antibiotic, in healthy adults and elderly individuals. The study demonstrates dose-proportional exposure, time-invariant pharmacokinetics, and a favorable safety profile, supporting further clinical development against resistant bacterial infections.

• ATM-Targeted TACE Silencing for Obesity-Induced Diabetes The

  2026-04-17

  This study demonstrates that gene silencing of TACE in visceral adipose tissue macrophages (ATMs) via the ATS-9R delivery system significantly reduces local and systemic inflammation in obese mice, improving insulin sensitivity. The approach establishes the feasibility of precision, non-viral gene delivery for obesity-related metabolic disorders.

• Tunable Human Intestinal Organoids: Balancing Self-Renewal a

  2026-04-16

  This study introduces a human intestinal organoid system where the balance between stem cell self-renewal and differentiation can be precisely modulated using small molecule pathway inhibitors. The approach enhances cellular diversity and proliferative capacity under a single culture condition, enabling scalable organoid applications for disease modeling and high-throughput research.

• Bufalin as a Cardiotonics: Protocols for Cancer Research

  2026-04-15

  Bufalin stands at the forefront of oncology research as both a cardiotonic steroid and a targeted apoptosis inducer. This article provides hands-on workflows, protocol optimizations, and troubleshooting strategies for leveraging high-purity Bufalin in advanced cancer models, with a focus on triple-negative breast cancer and hepatocellular carcinoma.

• Broad-Spectrum Bivalent mRNA Vaccine Efficacy Against SARS-C

  2026-04-14

  This preclinical study introduces RQ3025, a bivalent mRNA vaccine incorporating spike protein mutations from multiple SARS-CoV-2 variants, demonstrating broad-spectrum neutralization and a Th1-biased immune response in animal models. The findings highlight the potential of rational antigen design for next-generation COVID-19 vaccines targeting immune escape variants.

• MYC2-LBD40/42-CRL3BPM4 Module Fine-Tunes Botrytis Defense in

  2026-04-13

  This study reveals how the MYC2-LBD40/42-CRL3BPM4 regulatory module balances growth and Botrytis cinerea defense in tomato by modulating gene expression. The findings elucidate a dynamic repression/de-repression mechanism, offering new molecular targets for optimizing crop resilience.

• Cyclophosphamide: Protocol Optimization in Cancer Research

  2026-04-12

  Cyclophosphamide from APExBIO is a gold-standard alkylating chemotherapeutic agent, trusted for reproducible apoptosis induction and immune modulation in translational oncology. This guide delivers advanced workflows, troubleshooting tips, and cross-study insights to help researchers maximize data quality and experimental impact.

• Adenosine Triphosphate in Advanced Cellular Metabolism Resea

  2026-04-12

  Harnessing the full potential of Adenosine triphosphate (ATP) enables precise interrogation of mitochondrial metabolism, enzyme regulation, and purinergic signaling. This guide translates cutting-edge reference findings into actionable protocols and troubleshooting insights, leveraging APExBIO's high-purity ATP as a foundational tool for innovative metabolic research.

• Tropifexor (LJN452): Precision FXR Modulation for Barrier Re

  2026-04-11

  Tropifexor (LJN452) enables researchers to dissect FXR pathway biology with high potency and reproducibility. Its robust performance in epithelial barrier and metabolic disease models sets a new standard for translational research workflows.

• Applied Use of PYR-41, Inhibitor of Ubiquitin-Activating Enz

  2026-04-11

  PYR-41 unlocks high-precision control of the ubiquitin-proteasome system, enabling direct modulation of NF-κB signaling and advanced modeling of inflammation and apoptosis. This guide details actionable workflows, data-driven protocol refinements, and troubleshooting strategies to maximize research impact with PYR-41 in both cellular and in vivo systems.

• PreScission Protease: Precision Tag Cleavage for Protein ...

  2026-04-10

  PreScission Protease (PSP) stands apart as a recombinant fusion protease, enabling ultra-specific and low-temperature cleavage of fusion protein tags. Its robust performance in protein purification and versatility in advanced workflows, such as condensate biology, make it a trusted molecular biology enzyme tool.

• CX-5461: RNA Polymerase I Inhibitor for Advanced Cancer R...

  2026-04-09

  CX-5461 is redefining cancer research with its precise inhibition of Pol I-driven rRNA synthesis, enabling selective induction of autophagy and senescence in tumor models. This guide explores applied workflows, troubleshooting tips, and real-world strategies for leveraging CX-5461 in solid tumor studies, positioning it as a benchmark tool for translational cancer biology.

• LY2603618: Selective Chk1 Inhibitor for DNA Damage Respon...

  2026-04-08

  LY2603618 is a highly selective, ATP-competitive checkpoint kinase 1 (Chk1) inhibitor developed for robust DNA damage response inhibition and cell cycle arrest at the G2/M phase. This small molecule, supplied by APExBIO, demonstrates potent anti-tumor activity in non-small cell lung cancer models and enhances chemotherapy efficacy, especially in p53-mutant cells. Its rigorous biochemical and translational benchmarks position it as an indispensable tool in advanced cancer research.

466 records 22/32 page Previous Next First page 上5页 2122232425 下5页 Last page